Commitment to Hypertension Control During the COVID-19 Pandemic

Million Hearts Initiative Exemplars

Amena Abbas, MPH; Judy Hannan, RN, MPH; Haley Stolp, MPH; Fátima Coronado, MD, MPH; Laurence S. Sperling, MD


Prev Chronic Dis. 2022;19(8):e47 

In This Article

Evaluation Methods

MH queried its public and private sector partners to identify Hypertension Control Exemplars. Selection of Exemplars was based on the following criteria: 1) clinicians, medical centers, or health system support organizations that altered patient care or services or implemented new approaches in response to challenges presented by COVID-19 to prioritize hypertension control, 2) uniqueness of intervention, 3) community improvement individuals and organizations that served or prioritized under-resourced or patient populations who were disproportionately affected by COVID-19 or at risk for uncontrolled hypertension, and 4) community improvement individuals and organizations that demonstrated or documented qualitative or quantitative results of their hypertension control efforts and strategies (eg, percentage of patients with hypertension under control, number of patients reached, outcomes of implemented strategies, other benefits measured). A goal was to identify Exemplars across varied settings, including those delivering clinical care directly and organizations supporting health systems.

In addition to identifying eligible Exemplars, MH staff conducted virtual interviews by using a structured questionnaire to gather qualitative and quantitative data related to hypertension control efforts. The questionnaire gathered information on 1) general demographics and clinical information on the overall patient population and information specific to hypertensive patients, 2) adaptations to routine patient care or health services to monitor and control hypertension, and 3) outcomes and successes of hypertension control strategies, as well as challenges or barriers encountered during implementation. Interviews were audio recorded and transcribed. The Centers for Disease Control and Prevention (CDC) reviewed this study for human subjects' protection and determined it to be nonresearch.